Last reviewed · How we verify
HRS-9813 capsule mimetic — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
HRS-9813 capsule mimetic (HRS-9813 capsule mimetic) — Guangdong Hengrui Pharmaceutical Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HRS-9813 capsule mimetic TARGET | HRS-9813 capsule mimetic | Guangdong Hengrui Pharmaceutical Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HRS-9813 capsule mimetic CI watch — RSS
- HRS-9813 capsule mimetic CI watch — Atom
- HRS-9813 capsule mimetic CI watch — JSON
- HRS-9813 capsule mimetic alone — RSS
Cite this brief
Drug Landscape (2026). HRS-9813 capsule mimetic — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-9813-capsule-mimetic. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab